PHASE 2 EXPANDED TRIALS : Scientists give the vaccine to hundreds of people split into groups, such as children and the elderly, to see if the vaccine acts differently in them. Filter the list of vaccines: All vaccines Phase 2 Preclinical Phase 3 Phase 1 Approved Genetic Vaccines Vaccines that deliver one or more of the coronavirus's own genes into our cells to provoke an immune response.

Previous studies have shown that vaccine hesitancy is a common phenomenon globally, with variability in the cited reasons behind refusal of vaccine acceptance [11-13]. The most common reasons included: perceived risks vs. benefits, certain religious beliefs and lack of knowledge and awareness [14-16]. The aforementioned reasons can be applied to COVID-19 vaccine hesitancy, as shown by the recent publications that showed a strong correlation between intent to get coronavirus vaccines and its perceived safety , association of the negative attitude towards COVID-19 vaccines and unwillingness to get the vaccines , and the association of religiosity with lower intention to get COVID-19 vaccines. For the the three three studies studies conducted conducted among amongparents/guardians, parents/guardians, the the vaccine vaccine acceptance acceptance For than 70%. 70%. For the two two studies studies among among University University students, students, the the vaccine vaccine rates were more than, staff), and and 86.1% 86.1% in in Italy.

COVID-19 Vaccine Frequently Asked Questions ABOUT THE VACCINE HOW DOES COVID-19 VACCINE WORK? Vaccines work with your body's natural defenses so your body will be ready to ght the virus if you are exposed. VACCINE EFFECTIVENESS DO THE VACCINES WORK DIFFERENTLY OR HAVE DIFFERNT SIDE EFFECTS FOR PEOPLE OF DIVERSE AGES, RACIAL BACKGROUNDS, SEXES, AND OTHER DIFFERENCES? Trial results have shown that the vaccines are safe and work well for adults of all ages, races, genders, and ethnic backgrounds.

4 The recombinant adenovirus route to protection is shared with the Oxford- AstraZeneca vaccine, which uses a chimpanzee adenovirus,5 the Johnson 1 & Johnson vaccine that uses only Ad266 whose detailed results are expected soon, and the CanSinoBIOBeijing Institute of Biotechnology Ad5-based vaccine whose phase 3 trial began in September, 2020.7 The carrier viruses are modified and cannot initiate a productive infection; they enter cells, express the spike protein, and then stop, although a highsensitivity analysis also showed that a few Ad genes were expressed, albeit at a low level. No serious adverse events considered related to the vaccine were recorded, but serious adverse events unrelated to the vaccine were reported in 45 participants from the vaccine group and 23 participants from the placebo group.

Individuals who would wait to take the vaccine compared to individuals who would take the vaccine; individuals who would not take the vaccine compared to individuals who would take the vaccine; individuals who would not take the vaccine compared to individuals who would wait to take the vaccine. The proportion of individuals who would refuse to take the vaccine was similar to the prevalence reported by other studies, which has mainly ranged between 4% and 14.2% , although one study in the USA reported that 31% of the participants were unwilling to take the COVID19 vaccine while another reported that 20% of the participants were unwilling to take the COVID-19 vaccine due to the collateral effects and 14% because they do not need the vaccine.

According to data from the US Vaccine Adverse Event Reporting System, about 372 out of every million administered doses of the mRNA vaccines lead to a report of non-serious reactions. What do researchers know about the rare, but severe, allergic reactions to the vaccines? The Moderna vaccine elicits about three anaphylactic reactions per million doses administered, and the Pfizer-BioNTech vaccine triggers five reactions per million doses, according to VAERS data.

Feature THE RACE FOR AN ARRAY OF VACCINES CORONAVIRUS VACCINES All vaccines aim to expose the body to an antigen that won't cause disease, but will provoke an immune response that can block or kill the virus if a person becomes infected. Coronavirus peptide DNA vaccine DNA Coronavirus spike gene Body Immune response RNA vaccine RNA RNA is often encased in a lipid coat so it can enter cells VIRAL-VECTOR VACCINES PROTEIN-BASED VACCINES Around 25 groups say they are working on viral-vector vaccines.